NCT05807529View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Symptomatic Knee Osteoarthritis

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

November 3, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Osteoarthritis, Knee

Interventions

DRUG

2ccPA

"2-carba-cyclic phosphatidic acid (2ccPA) is a first-in-class phospholipase autotaxin (ATX) inhibitor that may act as a disease-modifying drug and may relieve OA associated symptoms.~Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29"

DRUG

Placebo

"Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29"

Trial Locations (1)

Unknown

Tri-Service General Hospital, Taipei

All Listed Sponsors

lead

Orient Europharma Co., Ltd.

INDUSTRY

NCT05807529 - A Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Symptomatic Knee Osteoarthritis | Biotech Hunter | Biotech Hunter